Randomized Trialvery high evidence
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The New England journal of medicine·December 14, 2023·PMID 37952131
Why it mattersThis is the first large RCT to demonstrate that a GLP-1 receptor agonist reduces major adverse cardiovascular events in patients without diabetes, expanding the evidence for cardiovascular risk reduction beyond glucose-lowering effects.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled